Partners Astrazeneca and Merck have won @US_FDA approval for the MEK 1/2 inhibitor Koselugo (selumetinib) for the treatment of pediatric patients with neurofibromatosis type 1, a genetic disorder of the nervous system causing tumors to grow on nerves $AZN $MRK